Epstein-barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis-association and causation

Viruses

Volumn 4, Issue 12, 2012, Pages 3701-3730

  Lossius, Andreas ^a   Johansen, Jorunn N ^a   Torkildsen, Øivind ^b   Vartdal, Frode ^a,d   Holmoy, Trygve ^c,d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Autoimmunity; B cells; Epstein Barr virus; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus; T cells

Indexed keywords

EPITOPE; T LYMPHOCYTE RECEPTOR;

AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BYSTANDER EFFECT; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHIMERA; DISEASE ASSOCIATION; EPIDEMIOLOGICAL DATA; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION; HUMAN; IMMUNOLOGY; INFLAMMATION; INNATE IMMUNITY; MOLECULAR MIMICRY; MONONUCLEOSIS; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; RETROVIRUS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS ACTIVATION; VIRUS GENE; VIRUS LOAD;

ARTHRITIS, RHEUMATOID; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MULTIPLE SCLEROSIS;

HUMAN HERPESVIRUS 4;

EID: 84871899004     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v4123701     Document Type: Review

References (225)

1. Lessard, C.J.; Ice, J.A.; Adrianto, I.; Wiley, G.B.; Kelly, J.A.; Gaffney, P.M.; Montgomery, C.G.; Moser, K.L. The genomics of autoimmune disease in the era of genome-wide association studies and beyond. Autoimmunity reviews 2012, 11, 267-275.
2. Bogdanos, D.P.; Smyk, D.S.; Rigopoulou, E.I.; Mytilinaiou, M.G.; Heneghan, M.A.; Selmi, C.; Gershwin, M.E. Twin studies in autoimmune disease: genetics, gender and environment. Journal of Autoimmunity 2012, 38, 156-169.
3. Disanto, G.; Chaplin, G.; Morahan, J.M.; Giovannoni, G.; Hypponen, E.; Ebers, G.C.; Ramagopalan, S.V. Month of birth, vitamin D and risk of immune mediated disease: A case control study. BMC medicine 2012, 10, 69.
4. Moroni, L.; Bianchi, I.; Lleo, A. Geoepidemiology, gender and autoimmune disease. Autoimmunity reviews 2012, 11, 386-392.
5. Handel, A.E.; Giovannoni, G.; Ebers, G.C.; Ramagopalan, S.V. Environmental factors and their timing in adult-onset multiple sclerosis. Nature reviews. Neurology 2010, 6, 156-166.
6. Chevassut, K. Aetiology of disseminated sclerosis. Lancet 1930, 215, 552-560.
7. Howard-Jones, N. Fake! Br. Med. J. (Clin. Res. Ed.) 1982, 284, 511.
8. Goswami, K.K.; Randall, R.E.; Lange, L.S.; Russell, W.C. Antibodies against the paramyxovirus SV5 in the cerebrospinal fluids of some multiple sclerosis patients. Nature 1987, 327, 244-247.
9. Vandvik, B.; Norrby, E., Paramyxovirus SV5 and multiple sclerosis. Nature 1989, 338, 769-771.
10. Dalldorf, G.; Carvalho, R.P.; Jamra, M.; Frost, P.; Erlich, D.; Marigo, C. The lymphomas of Brazilian children. JAMA: the Journal of the American Medical Association 1969, 208, 1365-1368.
11. James, J.A.; Neas, B.R.; Moser, K.L.; Hall, T.; Bruner, G.R.; Sestak, A.L.; Harley, J.B. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis and Rheumatism 2001, 44, 1122-1126.
12. McClain, M.T.; Poole, B.D.; Bruner, B.F.; Kaufman, K.M.; Harley, J.B.; James, J.A. An altered immune response to Epstein-Barr nuclear antigen 1 in pediatric systemic lupus erythematosus. Arthritis and Rheumatism 2006, 54, 360-368.
13. Berkun, Y.; Zandman-Goddard, G.; Barzilai, O.; Boaz, M.; Sherer, Y.; Larida, B.; Blank, M.; Anaya, J.M.; Shoenfeld, Y. Infectious antibodies in systemic lupus erythematosus patients. Lupus 2009, 18, 1129-1135.
14. Esen, B.A.; Yilmaz, G.; Uzun, S.; Ozdamar, M.; Aksozek, A.; Kamali, S.; Turkoglu, S.; Gul, A.; Ocal, L.; Aral, O.; et al. Serologic response to Epstein-Barr virus antigens in patients with systemic lupus erythematosus: A controlled study. Rheumatology International 2012, 32, 79-83.
15. Draborg, A.; Jorgensen, J.; Muller, H.; Nielsen, C.; Jacobsen, S.; Iversen, L.; Theander, E.; Nielsen, L.; Houen, G.; Duus, K. Epstein-Barr virus early antigen diffuse (EBV-EA/D)-directed immunoglobulin A antibodies in systemic lupus erythematosus patients. Scandinavian Journal of Rheumatology 2012, 41, 280-289.
16. James, J.A.; Kaufman, K.M.; Farris, A.D.; Taylor-Albert, E.; Lehman, T.J.; Harley, J.B. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. The Journal of Clinical Investigation 1997, 100, 3019-3026.
17. Ascherio, A.; Munch, M. Epstein-Barr virus and multiple sclerosis. Epidemiology 2000, 11, 220-224.
18. Alotaibi, S.; Kennedy, J.; Tellier, R.; Stephens, D.; Banwell, B. Epstein-Barr virus in pediatric multiple sclerosis. JAMA: the Journal of the American Medical Association 2004, 291, 1875-1879.
19. Levin, L.I.; Munger, K.L.; O'Reilly, E.J.; Falk, K.I.; Ascherio, A. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Annals of Neurology 2010, 67, 824-830.
20. Pakpoor, J.; Disanto, G.; Gerber, J.E.; Dobson, R.; Meier, U.C.; Giovannoni, G.; Ramagopalan, S.V. The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. Mult. Scler. 2012, doi: 10.1177/1352458512449682.
21. Evans, A.S.; Rothfield, N.F.; Niederman, J.C. Raised antibody titres to E.B. virus in systemic lupus erythematosus. Lancet 1971, 1, 167-168.
22. Larsen, P.D.; Bloomer, L.C.; Bray, P.F. Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis. Neurology 1985, 35, 435-438.
23. Shirodaria, P.V.; Haire, M.; Fleming, E.; Merrett, J.D.; Hawkins, S.A.; Roberts, S.D. Viral antibody titers. Comparison in patients with multiple sclerosis and rheumatoid arthritis. Archives of Neurology 1987, 44, 1237-1241.
24. Ascherio, A.; Munger, K.L.; Lennette, E.T.; Spiegelman, D.; Hernan, M.A.; Olek, M.J.; Hankinson, S.E.; Hunter, D.J. Epstein-Barr virus antibodies and risk of multiple sclerosis: A prospective study. JAMA: the Journal of the American Medical Association 2001, 286, 3083-3088.
25. McClain, M.T.; Bruner, T.L.; Dennis, G.J.; Harley, J.B.; James, J.A. The temporal relationship between the onset of anti-EBNA-1 and lupus autoimmunity supports a role for EBV in the development if SLE. Arthritis and Rheumatism 2003, 48, 674.
26. Heinlen, L.D.; McClain, M.T.; Dennis, G.J.; Rubertone, M.V.; Harley, J.B.; James, J.A. The development of antibodies targeting Epstein-Barr virus closely parallels autoimmune progression near the onset of SLE. Arthritis and Rheumatism 2003, 48, 662.
27. Levin, L.I.; Munger, K.L.; Rubertone, M.V.; Peck, C.A.; Lennette, E.T.; Spiegelman, D.; Ascherio, A. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA: the Journal of the American Medical Association 2005, 293, 2496-2500.
28. Lunemann, J.D.; Tintore, M.; Messmer, B.; Strowig, T.; Rovira, A.; Perkal, H.; Caballero, E.; Munz, C.; Montalban, X.; Comabella, M. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Annals of Neurology 2010, 67, 159-169.
29. Farrell, R.A.; Antony, D.; Wall, G.R.; Clark, D.A.; Fisniku, L.; Swanton, J.; Khaleeli, Z.; Schmierer, K.; Miller, D.H.; Giovannoni, G. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 2009, 73, 32-38.
30. Ingram, G.; Bugert, J.J.; Loveless, S.; Robertson, N.P. Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity. European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies 2010, 17, 1386-1389.
31. Wandinger, K.; Jabs, W.; Siekhaus, A.; Bubel, S.; Trillenberg, P.; Wagner, H.; Wessel, K.; Kirchner, H.; Hennig, H. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 2000, 55, 178-184.
32. Buljevac, D.; van Doornum, G.J.; Flach, H.Z.; Groen, J.; Osterhaus, A.D.; Hop, W.; van Doorn, P.A.; van der Meche, F.G.; Hintzen, R.Q. Epstein-Barr virus and disease activity in multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry 2005, 76, 1377-1381.
33. Torkildsen, O.; Nyland, H.; Myrmel, H.; Myhr, K.M. Epstein-Barr virus reactivation and multiple sclerosis. European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies 2008, 15, 106-108.
34. Chen, C.J.; Lin, K.H.; Lin, S.C.; Tsai, W.C.; Yen, J.H.; Chang, S.J.; Lu, S.N.; Liu, H.W. High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: Case control studies. The Journal of Rheumatology 2005, 32, 44-47.
35. Catalano, M.A.; Carson, D.A.; Slovin, S.F.; Richman, D.D.; Vaughan, J.H. Antibodies to Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis. Proceedings of the National Academy of Sciences of the United States of America 1979, 76, 5825-5828.
36. Ferrell, P.B.; Aitcheson, C.T.; Pearson, G.R.; Tan, E.M. Seroepidemiological study of relationships between Epstein-Barr virus and rheumatoid arthritis. The Journal of Clinical Investigation 1981, 67, 681-687.
37. Lunemann, J.D.; Frey, O.; Eidner, T.; Baier, M.; Roberts, S.; Sashihara, J.; Volkmer, R.; Cohen, J.I.; Hein, G.; Kamradt, T.; et al. Increased frequency of EBV-specific effector memory CD8+ T-cells correlates with higher viral load in rheumatoid arthritis. J. Immunol 2008, 181, 991-1000.
38. Goldstein, B.L.; Chibnik, L.B.; Karlson, E.W.; Costenbader, K.H., Epstein-Barr virus serologic abnormalities and risk of rheumatoid arthritis among women. Autoimmunity 2012, 45, 161-168.
39. Yazbek, M.A.; Barros-Mazon, S.; Rossi, C.L.; Londe, A.C.; Costallat, L.T.; Bertolo, M.B. Association analysis of anti-Epstein-Barr nuclear antigen-1 antibodies, anti-cyclic citrullinated peptide antibodies, the shared epitope and smoking status in Brazilian patients with rheumatoid arthritis. Clinics 2011, 66, 1401-1406.
40. Sundstrom, P.; Nystrom, M.; Ruuth, K.; Lundgren, E. Antibodies to specific EBNA-1 domains and HLA DRB1*1501 interact as risk factors for multiple sclerosis. Journal of Neuroimmunology 2009, 215, 102-107.
41. Sundqvist, E.; Sundstrom, P.; Linden, M.; Hedstrom, A.K.; Aloisi, F.; Hillert, J.; Kockum, I.; Alfredsson, L.; Olsson, T., Epstein-Barr virus and multiple sclerosis: Interaction with HLA. Genes and Immunity 2012, 13, 14-20.
42. Mechelli, R.; Anderson, J.; Vittori, D.; Coarelli, G.; Annibali, V.; Cannoni, S.; Aloisi, F.; Salvetti, M.; James, J.A.; Ristori, G. Epstein-Barr virus nuclear antigen-1 B-cell epitopes in multiple sclerosis twins. Mult. Scler. 2011, 17, 1290-1294.
43. Lunemann, J.D.; Huppke, P.; Roberts, S.; Bruck, W.; Gartner, J.; Munz, C. Broadened and elevated humoral immune response to EBNA1 in pediatric multiple sclerosis. Neurology 2008, 71, 1033-1035.
44. Petersen, J.; Rhodes, G.; Roudier, J.; Vaughan, J.H. Altered immune response to glycine-rich sequences of Epstein-Barr nuclear antigen-1 in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis and Rheumatism 1990, 33, 993-1000.
45. Cremer, N.E.; Hurwitz, D.; Quismorio, F.P.; Lennette, E.H.; Friou, G.J. Antiviral antibodies in rheumatoid synovial fluid and cryoprecipitates. Clinical and experimental immunology 1974, 18, 27-37.
46. Alspaugh, M.A.; Henle, G.; Lennette, E.T.; Henle, W. Elevated levels of antibodies to Epstein-Barr virus antigens in sera and synovial fluids of patients with rheumatoid arthritis. The Journal of Clinical Investigation 1981, 67, 1134-1140.
47. Musiani, M.; Zerbini, M.; Ferri, S.; Plazzi, M.; Gentilomi, G.; La Placa, M. Comparison of the immune response to Epstein-Barr virus and cytomegalovirus in sera and synovial fluids of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 1987, 46, 837-842.
48. Cepok, S.; Zhou, D.; Srivastava, R.; Nessler, S.; Stei, S.; Bussow, K.; Sommer, N.; Hemmer, B., Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. The Journal of Clinical Investigation 2005, 115, 1352-1360.
49. Jaquiery, E.; Jilek, S.; Schluep, M.; Meylan, P.; Lysandropoulos, A.; Pantaleo, G.; Du Pasquier, R.A. Intrathecal immune responses to EBV in early MS. European Journal of Immunology 2010, 40, 878-887.
50. Otto, C.; Oltmann, A.; Stein, A.; Frenzel, K.; Schroeter, J.; Habbel, P.; Gartner, B.; Hofmann, J.; Ruprecht, K. Intrathecal EBV antibodies are part of the polyspecific immune response in multiple sclerosis. Neurology 2011, 76, 1316-1321.
51. Cohen, J.I., Epstein-Barr virus infection. The New England Journal of Medicine 2000, 343, 481-492.
52. Handel, A.E.; Williamson, A.J.; Disanto, G.; Handunnetthi, L.; Giovannoni, G.; Ramagopalan, S.V. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PloS one 2010, 5, e12496.
53. Strom, B.L.; Reidenberg, M.M.; West, S.; Snyder, E.S.; Freundlich, B.; Stolley, P.D. Shingles, allergies, family medical history, oral contraceptives, and other potential risk factors for systemic lupus erythematosus. American Journal of Epidemiology 1994, 140, 632-642.
54. Cooper, G.S.; Dooley, M.A.; Treadwell, E.L.; St Clair, E.W.; Gilkeson, G.S. Risk factors for development of systemic lupus erythematosus: allergies, infections, and family history. Journal of Clinical Epidemiology 2002, 55, 982-989.
55. Ulff-Moller, C.J.; Nielsen, N.M.; Rostgaard, K.; Hjalgrim, H.; Frisch, M. Epstein-Barr virus-associated infectious mononucleosis and risk of systemic lupus erythematosus. Rheumatology 2010, 49, 1706-1712.
56. Pedersen, M.; Jacobsen, S.; Klarlund, M.; Pedersen, B.V.; Wiik, A.; Wohlfahrt, J.; Frisch, M. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Research & Therapy 2006, 8, doi: 10.1186/ar2022.
57. Tsokos, G.C.; Magrath, I.T.; Balow, J.E. Epstein-Barr virus induces normal B-cell responses but defective suppressor T-cell responses in patients with systemic lupus erythematosus. J. Immunol. 1983, 131, 1797-1801.
58. Berner, B.R.; Tary-Lehmann, M.; Yonkers, N.L.; Askari, A.D.; Lehmann, P.V.; Anthony, D.D., Phenotypic and functional analysis of EBV-specific memory CD8 cells in SLE. Cellular Immunology 2005, 235, 29-38.
59. Larsen, M.; Sauce, D.; Deback, C.; Arnaud, L.; Mathian, A.; Miyara, M.; Boutolleau, D.; Parizot, C.; Dorgham, K.; Papagno, L.; et al. Exhausted cytotoxic control of Epstein-Barr virus in human lupus. PLoS pathogens 2011, 7, e1002328.
60. Kang, I.; Quan, T.; Nolasco, H.; Park, S.H.; Hong, M.S.; Crouch, J.; Pamer, E.G.; Howe, J.G.; Craft, J. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J. Immunol. 2004, 172, 1287-1294.
61. Slaughter, L.; Carson, D.A.; Jensen, F.C.; Holbrook, T.L.; Vaughan, J.H. in vitro effects of Epstein-Barr virus on peripheral blood mononuclear cells from patients with rheumatoid arthritis and normal subjects. The Journal of Experimental Medicine 1978, 148, 1429-1434.
62. Tosato, G.; Steinberg, A.D.; Blaese, R.M. Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. The New England Journal of Medicine 1981, 305, 1238-1243.
63. Toussirot, E.; Wendling, D.; Tiberghien, P.; Luka, J.; Roudier, J. Decreased T-cell precursor frequencies to Epstein-Barr virus glycoprotein Gp110 in peripheral blood correlate with disease activity and severity in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2000, 59, 533-538.
64. Klatt, T.; Ouyang, Q.; Flad, T.; Koetter, I.; Buhring, H.J.; Kalbacher, H.; Pawelec, G.; Muller, C.A. Expansion of peripheral CD8+ CD28-T-cells in response to Epstein-Barr virus in patients with rheumatoid arthritis. The Journal of Rheumatology 2005, 32, 239-251.
65. Fraser, K.B.; Haire, M.; Millar, J.H.; McCrea, S. Increased tendency to spontaneous in vitro lymphocyte transformation in clinically active multiple sclerosis. Lancet 1979, 2, 175-176.
66. Craig, J.C.; Haire, M.; Merrett, J.D. T-cell-mediated suppression of Epstein-Barr virus-induced B lymphocyte activation in multiple sclerosis. Clinical Immunology and Immunopathology 1988, 48, 253-260.
67. Pender, M.P.; Csurhes, P.A.; Lenarczyk, A.; Pfluger, C.M.; Burrows, S.R. Decreased T-cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry 2009, 80, 498-505.
68. Hollsberg, P.; Hansen, H.J.; Haahr, S. Altered CD8+ T-cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis. Clinical and Experimental Immunology 2003, 132, 137-143.
69. Jilek, S.; Schluep, M.; Meylan, P.; Vingerhoets, F.; Guignard, L.; Monney, A.; Kleeberg, J.; Le Goff, G.; Pantaleo, G.; Du Pasquier, R.A. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain: A Journal of Neurology 2008, 131, 1712-1721.
70. Lunemann, J.D.; Edwards, N.; Muraro, P.A.; Hayashi, S.; Cohen, J.I.; Munz, C.; Martin, R., Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T-cells in multiple sclerosis. Brain: A Journal of Neurology 2006, 129, 1493-1506.
71. David-Ameline, J.; Lim, A.; Davodeau, F.; Peyrat, M.A.; Berthelot, J.M.; Semana, G.; Pannetier, C.; Gaschet, J.; Vie, H.; Even, J.; et al. Selection of T-cells reactive against autologous B lymphoblastoid cells during chronic rheumatoid arthritis. J. Immunol. 1996, 157, 4697-4706.
72. Scotet, E.; David-Ameline, J.; Peyrat, M.A.; Moreau-Aubry, A.; Pinczon, D.; Lim, A.; Even, J.; Semana, G.; Berthelot, J.M.; Breathnach, R.; et al. T-cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis. The Journal of Experimental Medicine 1996, 184, 1791-1800.
73. Scotet, E.; Peyrat, M.A.; Saulquin, X.; Retiere, C.; Couedel, C.; Davodeau, F.; Dulphy, N.; Toubert, A.; Bignon, J.D.; Lim, A.; et al. Frequent enrichment for CD8 T-cells reactive against common herpes viruses in chronic inflammatory lesions: towards a reassessment of the physiopathological significance of T-cell clonal expansions found in autoimmune inflammatory processes. European Journal of Immunology 1999, 29, 973-985.
74. Tan, L.C.; Mowat, A.G.; Fazou, C.; Rostron, T.; Roskell, H.; Dunbar, P.R.; Tournay, C.; Romagne, F.; Peyrat, M.A.; Houssaint, E.; et al. Specificity of T-cells in synovial fluid: high frequencies of CD8(+) T-cells that are specific for certain viral epitopes. Arthritis Research 2000, 2, 154-164.
75. Holmoy, T.; Vartdal, F. Cerebrospinal fluid T-cells from multiple sclerosis patients recognize autologous Epstein-Barr virus-transformed B-cells. Journal of Neurovirology 2004, 10, 52-56.
76. Holmoy, T.; Kvale, E.O.; Vartdal, F. Cerebrospinal fluid CD4+ T-cells from a multiple sclerosis patient cross-recognize Epstein-Barr virus and myelin basic protein. Journal of Neurovirology 2004, 10, 278-283.
77. Lossius, A.; Vartdal, F.; Holmoy, T. Vitamin D sensitive EBNA-1 specific T-cells in the cerebrospinal fluid of patients with multiple sclerosis. Journal of Neuroimmunology 2011, 240-241, 87-96.
78. Moon, U.Y.; Park, S.J.; Oh, S.T.; Kim, W.U.; Park, S.H.; Lee, S.H.; Cho, C.S.; Kim, H.Y.; Lee, W.K.; Lee, S.K. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Research & Therapy 2004, 6, 295-302.
79. Yu, S.F.; Wu, H.C.; Tsai, W.C.; Yen, J.H.; Chiang, W.; Yuo, C.Y.; Lu, S.N.; Chiang, L.C.; Chen, C.J. Detecting Epstein-Barr virus DNA from peripheral blood mononuclear cells in adult patients with systemic lupus erythematosus in Taiwan. Medical Microbiology and Immunology 2005, 194, 115-120.
80. Gross, A.J.; Hochberg, D.; Rand, W.M.; Thorley-Lawson, D.A. EBV and systemic lupus erythematosus: a new perspective. J. Immunol. 2005, 174, 6599-6607.
81. Tosato, G.; Steinberg, A.D.; Yarchoan, R.; Heilman, C.A.; Pike, S.E.; De Seau, V.; Blaese, R.M., Abnormally elevated frequency of Epstein-Barr virus-infected B-cells in the blood of patients with rheumatoid arthritis. The Journal of Clinical Investigation 1984, 73, 1789-1795.
82. Blaschke, S.; Schwarz, G.; Moneke, D.; Binder, L.; Muller, G.; Reuss-Borst, M. Epstein-Barr virus infection in peripheral blood mononuclear cells, synovial fluid cells, and synovial membranes of patients with rheumatoid arthritis. The Journal of Rheumatology 2000, 27, 866-873.
83. Balandraud, N.; Meynard, J.B.; Auger, I.; Sovran, H.; Mugnier, B.; Reviron, D.; Roudier, J.; Roudier, C. Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction. Arthritis and Rheumatism 2003, 48, 1223-1228.
84. Balandraud, N.; Guis, S.; Meynard, J.B.; Auger, I.; Roudier, J.; Roudier, C. Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis. Arthritis and Rheumatism 2007, 57, 762-767.
85. Lindsey, J.W.; Hatfield, L.M.; Crawford, M.P.; Patel, S. Quantitative PCR for Epstein-Barr virus DNA and RNA in multiple sclerosis. Mult. Scler. 2009, 15, 153-158.
86. Lucas, R.M.; Ponsonby, A.L.; Dear, K.; Valery, P.; Pender, M.P.; Burrows, J.M.; Burrows, S.R.; Chapman, C.; Coulthard, A.; Dwyer, D.E.; et al. Current and past Epstein-Barr virus infection in risk of initial CNS demyelination. Neurology 2011, 77, 371-379.
87. Wagner, H.J.; Munger, K.L.; Ascherio, A. Plasma viral load of Epstein-Barr virus and risk of multiple sclerosis. European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies 2004, 11, 833-834.
88. Alspaugh, M.A.; Shoji, H.; Nonoyama, M. A search for rheumatoid arthritis-associated nuclear antigen and Epstein-Barr virus specific antigens or genomes in tissues and cells from patients with rheumatoid arthritis. Arthritis and Rheumatism 1983, 26, 712-720.
89. Fox, R.I.; Chilton, T.; Rhodes, G.; Vaughan, J.H. Lack of reactivity of rheumatoid arthritis synovial membrane DNA with cloned Epstein Barr virus DNA probes. J. Immunol. 1986, 137, 498-501.
90. Brousset, P.; Caulier, M.; Cantagrel, A.; Dromer, C.; Mazieres, B.; Delsol, G. Absence of Epstein-Barr virus carrying cells in synovial membranes and subcutaneous nodules of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 1993, 52, 608-609.
91. Takei, M.; Mitamura, K.; Fujiwara, S.; Horie, T.; Ryu, J.; Osaka, S.; Yoshino, S.; Sawada, S. Detection of Epstein-Barr virus-encoded small RNA 1 and latent membrane protein 1 in synovial lining cells from rheumatoid arthritis patients. International Immunology 1997, 9, 739-743.
92. Takeda, T.; Mizugaki, Y.; Matsubara, L.; Imai, S.; Koike, T.; Takada, K. Lytic Epstein-Barr virus infection in the synovial tissue of patients with rheumatoid arthritis. Arthritis and Rheumatism 2000, 43, 1218-1225.
93. Niedobitek, G.; Lisner, R.; Swoboda, B.; Rooney, N.; Fassbender, H.G.; Kirchner, T.; Aigner, T.; Herbst, H. Lack of evidence for an involvement of Epstein-Barr virus infection of synovial membranes in the pathogenesis of rheumatoid arthritis. Arthritis and Rheumatism 2000, 43, 151-154.
94. Mehraein, Y.; Lennerz, C.; Ehlhardt, S.; Remberger, K.; Ojak, A.; Zang, K.D. Latent Epstein-Barr virus (EBV) infection and cytomegalovirus (CMV) infection in synovial tissue of autoimmune chronic arthritis determined by RNA-and DNA-in situ hybridization. Modern Pathology: An Official Journal of the US and Canadian Academy of Pathology Inc 2004, 17, 781-789.
95. Zhang, L.; Nikkari, S.; Skurnik, M.; Ziegler, T.; Luukkainen, R.; Mottonen, T.; Toivanen, P. Detection of herpesviruses by polymerase chain reaction in lymphocytes from patients with rheumatoid arthritis. Arthritis and Rheumatism 1993, 36, 1080-1086.
96. Mousavi-Jazi, M.; Bostrom, L.; Lovmark, C.; Linde, A.; Brytting, M.; Sundqvist, V.A. Infrequent detection of cytomegalovirus and Epstein-Barr virus DNA in synovial membrane of patients with rheumatoid arthritis. The Journal of Rheumatology 1998, 25, 623-628.
97. Saal, J.G.; Krimmel, M.; Steidle, M.; Gerneth, F.; Wagner, S.; Fritz, P.; Koch, S.; Zacher, J.; Sell, S.; Einsele, H.; et al. Synovial Epstein-Barr virus infection increases the risk of rheumatoid arthritis in individuals with the shared HLA-DR4 epitope. Arthritis and Rheumatism 1999, 42, 1485-1496.
98. Hilton, D.A.; Love, S.; Fletcher, A.; Pringle, J.H. Absence of Epstein-Barr virus RNA in multiple sclerosis as assessed by in situ hybridisation. Journal of Neurology, Neurosurgery, and Psychiatry 1994, 57, 975-976.
99. Opsahl, M.L.; Kennedy, P.G. An attempt to investigate the presence of Epstein Barr virus in multiple sclerosis and normal control brain tissue. Journal of Neurology 2007, 254, 425-430.
100. Serafini, B.; Rosicarelli, B.; Franciotta, D.; Magliozzi, R.; Reynolds, R.; Cinque, P.; Andreoni, L.; Trivedi, P.; Salvetti, M.; Faggioni, A.; et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. The Journal of Experimental Medicine 2007, 204, 2899-2912.
101. Willis, S.N.; Stadelmann, C.; Rodig, S.J.; Caron, T.; Gattenloehner, S.; Mallozzi, S.S.; Roughan, J.E.; Almendinger, S.E.; Blewett, M.M.; Bruck, W. et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain: A Journal of Neurology 2009, 132, 3318-3328.
102. Peferoen, L.A.; Lamers, F.; Lodder, L.N.; Gerritsen, W.H.; Huitinga, I.; Melief, J.; Giovannoni, G.; Meier, U.; Hintzen, R.Q.; Verjans, G.M. et al. Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain: A Journal of Neurology 2010, 133, e137.
103. Fatima, N.; Toscano, M.P.; Hunter, S.B.; Cohen, C. Controversial role of Epstein-Barr virus in multiple sclerosis. Applied Immunohistochemistry & Molecular Morphology: AIMM / Official Publication of the Society for Applied Immunohistochemistry 2011, 19, 246-252.
104. Torkildsen, O.; Stansberg, C.; Angelskar, S.M.; Kooi, E.J.; Geurts, J.J.; van der Valk, P.; Myhr, K.M.; Steen, V.M.; Bo, L. Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. Brain Pathol. 2010, 20, 720-729.
105. Sargsyan, S.A.; Shearer, A.J.; Ritchie, A.M.; Burgoon, M.P.; Anderson, S.; Hemmer, B.; Stadelmann, C.; Gattenlohner, S.; Owens, G.P.; Gilden, D.; et al. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology 2010, 74, 1127-1135.
106. Lassmann, H.; Niedobitek, G.; Aloisi, F.; Middeldorp, J.M. Epstein-Barr virus in the multiple sclerosis brain: a controversial issue-report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain: A Journal of Neurology 2011, 134, 2772-2786.
107. Tzartos, J.S.; Khan, G.; Vossenkamper, A.; Cruz-Sadaba, M.; Lonardi, S.; Sefia, E.; Meager, A.; Elia, A.; Middeldorp, J.M.; Clemens, M. et al. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology 2012, 78, 15-23.
108. Thorley-Lawson, D.A.; Gross, A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. The New England Journal of Medicine 2004, 350, 1328-1337.
109. Tsurumi, T.; Fujita, M.; Kudoh, A. Latent and lytic Epstein-Barr virus replication strategies. Reviews in Medical Virology 2005, 15, 3-15.
110. He, B.; Raab-Traub, N.; Casali, P.; Cerutti, A. EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T-cell-independent Ig heavy chain class switching. J. Immunol. 2003, 171, 5215-5224.
111. Graham, J.P.; Arcipowski, K.M.; Bishop, G.A. Differential B-lymphocyte regulation by CD40 and its viral mimic, latent membrane protein 1. Immunological Reviews 2010, 237, 226-248.
112. Mancao, C.; Hammerschmidt, W. Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood 2007, 110, 3715-3721.
113. Pender, M.P. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends in Immunology 2003, 24, 584-588.
114. Pender, M.P. CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis. Autoimmune Diseases 2012, doi: 10.1155/2012/189096.
115. Swanson-Mungerson, M.A.; Caldwell, R.G.; Bultema, R.; Longnecker, R. Epstein-Barr virus LMP2A alters in vivo and in vitro models of B-cell anergy, but not deletion, in response to autoantigen. Journal of Virology 2005, 79, 7355-7362.
116. Wang, H.; Nicholas, M.W.; Conway, K.L.; Sen, P.; Diz, R.; Tisch, R.M.; Clarke, S.H. EBV latent membrane protein 2A induces autoreactive B-cell activation and TLR hypersensitivity. J. Immunol. 2006, 177, 2793-2802.
117. Roughan, J.E.; Thorley-Lawson, D.A. The intersection of Epstein-Barr virus with the germinal center. Journal of Virology 2009, 83, 3968-3976.
118. Tracy, S.I.; Kakalacheva, K.; Lunemann, J.D.; Luzuriaga, K.; Middeldorp, J.; Thorley-Lawson, D.A. Persistence of epstein-barr virus in self-reactive memory B-cells. Journal of Virology 2012, 86, 12330-12340.
119. Tokunaga, M.; Uemura, Y.; Tokudome, T.; Sato, E. Epstein-Barr virus-infected T-cells in infectious mononucleosis. Acta Pathologica Japonica 1993, 43, 146-147.
120. Anagnostopoulos, I.; Hummel, M.; Kreschel, C.; Stein, H. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood 1995, 85, 744-750.
121. Kimura, H.; Hoshino, Y.; Kanegane, H.; Tsuge, I.; Okamura, T.; Kawa, K.; Morishima, T. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001, 98, 280-286.
122. Dreyfus, D.H.; Nagasawa, M.; Pratt, J.C.; Kelleher, C.A.; Gelfand, E.W. Inactivation of NF-kappaB by EBV BZLF-1-encoded ZEBRA protein in human T-cells. J. Immunol. 1999, 163, 6261-6268.
123. Dreyfus, D.H.; Nagasawa, M.; Kelleher, C.A.; Gelfand, E.W. Stable expression of Epstein-Barr virus BZLF-1-encoded ZEBRA protein activates p53-dependent transcription in human Jurkat T-lymphoblastoid cells. Blood 2000, 96, 625-634.
124. Menet, A.; Speth, C.; Larcher, C.; Prodinger, W.M.; Schwendinger, M.G.; Chan, P.; Jager, M.; Schwarzmann, F.; Recheis, H.; Fontaine, M.; et al. Epstein-Barr virus infection of human astrocyte cell lines. Journal of Virology 1999, 73, 7722-7733.
125. Casiraghi, C.; Dorovini-Zis, K.; Horwitz, M.S. Epstein-Barr virus infection of human brain microvessel endothelial cells: a novel role in multiple sclerosis. Journal of Neuroimmunology 2011, 230, 173-177.
126. Posnett, D.N. Herpesviruses and autoimmunity. Curr. Opin. Investig. Drugs 2008, 9, 505-514.
127. Xu, D.; Brumm, K.; Zhang, L. The latent membrane protein 1 of Epstein-Barr virus (EBV) primes EBV latency cells for type I interferon production. The Journal of Biological Chemistry 2006, 281, 9163-9169.
128. Busch, L.K.; Bishop, G.A. The EBV transforming protein, latent membrane protein 1, mimics and cooperates with CD40 signaling in B lymphocytes. J. Immunol. 1999, 162, 2555-2561.
129. Burdin, N.; Peronne, C.; Banchereau, J.; Rousset, F. Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10. The Journal of Experimental Medicine 1993, 177, 295-304.
130. Karageorgas, T.P.; Tseronis, D.D.; Mavragani, C.P. Activation of type I interferon pathway in systemic lupus erythematosus: Association with distinct clinical phenotypes. Journal of Biomedicine & Biotechnology 2011, doi: 10.1155/2011/273907.
131. Baccala, R.; Hoebe, K.; Kono, D.H.; Beutler, B.; Theofilopoulos, A.N. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nature Medicine 2007, 13, 543-551.
132. Quan, T.E.; Roman, R.M.; Rudenga, B.J.; Holers, V.M.; Craft, J.E. Epstein-Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells. Arthritis and Rheumatism 2010, 62, 1693-1701.
133. Valente, R.M.; Ehlers, E.; Xu, D.; Ahmad, H.; Steadman, A.; Blasnitz, L.; Zhou, Y.; Kastanek, L.; Meng, B.; Zhang, L. Toll-like receptor 7 stimulates the expression of epstein-barr virus latent membrane protein 1. PloS one 2012, 7, e43317.
134. Serafini, B.; Severa, M.; Columba-Cabezas, S.; Rosicarelli, B.; Veroni, C.; Chiappetta, G.; Magliozzi, R.; Reynolds, R.; Coccia, E.M.; Aloisi, F. Epstein-Barr virus latent infection and BAFF expression in B-cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. Journal of Neuropathology and Experimental Neurology 2010, 69, 677-693.
135. Salamon, D.; Adori, M.; Ujvari, D.; Wu, L.; Kis, L.L.; Madapura, H.S.; Nagy, N.; Klein, G.; Klein, E. Latency type-dependent modulation of Epstein-Barr virus-encoded latent membrane protein 1 expression by type I interferons in B-cells. Journal of Virology 2012, 86, 4701-4707.
136. Kis, L.L.; Takahara, M.; Nagy, N.; Klein, G.; Klein, E. IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and in Burkitt lymphoma-and NK lymphoma-derived cell lines. Blood 2006, 107, 2928-2935.
137. Konforte, D.; Simard, N.; Paige, C.J. Interleukin-21 regulates expression of key Epstein-Barr virus oncoproteins, EBNA2 and LMP1, in infected human B-cells. Virology 2008, 374, 100-113.
138. Hulshof, S.; Montagne, L.; De Groot, C.J.; Van Der Valk, P. Cellular localization and expression patterns of interleukin-10, interleukin-4, and their receptors in multiple sclerosis lesions. Glia 2002, 38, 24-35.
139. Tzartos, J.S.; Craner, M.J.; Friese, M.A.; Jakobsen, K.B.; Newcombe, J.; Esiri, M.M.; Fugger, L. IL-21 and IL-21 receptor expression in lymphocytes and neurons in multiple sclerosis brain. The American Journal of Pathology 2011, 178, 794-802.
140. Cush, J.J.; Splawski, J.B.; Thomas, R.; McFarlin, J.E.; Schulze-Koops, H.; Davis, L.S.; Fujita, K.; Lipsky, P.E. Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis and Rheumatism 1995, 38, 96-104.
141. Alanara, T.; Karstila, K.; Moilanen, T.; Silvennoinen, O.; Isomaki, P. Expression of IL-10 family cytokines in rheumatoid arthritis: elevated levels of IL-19 in the joints. Scandinavian Journal of Rheumatology 2010, 39, 118-126.
142. Conigliaro, P.; Perricone, C.; Benson, R.A.; Garside, P.; Brewer, J.M.; Perricone, R.; Valesini, G. The type I IFN system in rheumatoid arthritis. Autoimmunity 2010, 43, 220-225.
143. Moura, R.A.; Cascao, R.; Perpetuo, I.; Canhao, H.; Vieira-Sousa, E.; Mourao, A.F.; Rodrigues, A.M.; Polido-Pereira, J.; Queiroz, M.V.; Rosario, H.S.; et al. Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival. Rheumatology (Oxford) 2011, 50, 278-282.
144. Grondal, G.; Gunnarsson, I.; Ronnelid, J.; Rogberg, S.; Klareskog, L.; Lundberg, I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clinical and Experimental Rheumatology 2000, 18, 565-570.
145. Dolff, S.; Abdulahad, W.H.; Westra, J.; Doornbos-van der Meer, B.; Limburg, P.C.; Kallenberg, C.G.; Bijl, M. Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus. Arthritis Research & Therapy 2011, 13, 157.
146. Daibata, M.; Speck, S.H.; Mulder, C.; Sairenji, T. Regulation of the BZLF1 promoter of Epstein-Barr virus by second messengers in anti-immunoglobulin-treated B-cells. Virology 1994, 198, 446-454.
147. Laichalk, L.L.; Thorley-Lawson, D.A. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. Journal of Virology 2005, 79, 1296-1307.
148. Souto-Carneiro, M.M.; Mahadevan, V.; Takada, K.; Fritsch-Stork, R.; Nanki, T.; Brown, M.; Fleisher, T.A.; Wilson, M.; Goldbach-Mansky, R.; Lipsky, P.E. Alterations in peripheral blood memory B-cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Research & Therapy 2009, 11, 84.
149. Corcione, A.; Casazza, S.; Ferretti, E.; Giunti, D.; Zappia, E.; Pistorio, A.; Gambini, C.; Mancardi, G.L.; Uccelli, A.; Pistoia, V. Recapitulation of B-cell differentiation in the central nervous system of patients with multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America 2004, 101, 11064-11069.
150. Lee-Chang, C.; Top, I.; Zephir, H.; Dubucquoi, S.; Trauet, J.; Dussart, P.; Prin, L.; Vermersch, P. Primed status of transitional B-cells associated with their presence in the cerebrospinal fluid in early phases of multiple sclerosis. Clin. Immunol. 2011, 139, 12-20.
151. Prineas, J.W. Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord. Science 1979, 203, 1123-1125.
152. Serafini, B.; Rosicarelli, B.; Magliozzi, R.; Stigliano, E.; Aloisi, F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004, 14, 164-174.
153. Perl, A.; Fernandez, D.; Telarico, T.; Phillips, P.E. Endogenous retroviral pathogenesis in lupus. Current Opinion in Rheumatology 2010, 22, 483-492.
154. Sutkowski, N.; Conrad, B.; Thorley-Lawson, D.A.; Huber, B.T. Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity 2001, 15, 579-589.
155. Sicat, J.; Sutkowski, N.; Huber, B.T. Expression of human endogenous retrovirus HERV-K18 superantigen is elevated in juvenile rheumatoid arthritis. The Journal of Rheumatology 2005, 32, 1821-1831.
156. Tai, A.K.; O'Reilly, E.J.; Alroy, K.A.; Simon, K.C.; Munger, K.L.; Huber, B.T.; Ascherio, A. Human endogenous retrovirus-K18 Env as a risk factor in multiple sclerosis. Mult. Scler. 2008, 14, 1175-1180.
157. Virtanen, J.O.; Jacobson, S. Viruses and multiple sclerosis. CNS & Neurological Disorders Drug Targets 2012, 11, 528-544.
158. Junker, A.; Ivanidze, J.; Malotka, J.; Eiglmeier, I.; Lassmann, H.; Wekerle, H.; Meinl, E.; Hohlfeld, R.; Dornmair, K. Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain: A Journal of Neurology 2007, 130, 2789-2799.
159. Kurokawa, M.; Kato, T.; Masuko-Hongo, K.; Ueda, S.; Kobata, T.; Okubo, M.; Nishimaki, T.; Akaza, T.; Yoshino, S.; Kasukawa, R.; et al. Characterisation of T-cell clonotypes that accumulated in multiple joints of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 1999, 58, 546-553.
160. Cantaert, T.; Brouard, S.; Thurlings, R.M.; Pallier, A.; Salinas, G.F.; Braud, C.; Klarenbeek, P.L.; de Vries, N.; Zhang, Y.; Soulillou, J.P.; et al. Alterations of the synovial T-cell repertoire in anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis and Rheumatism 2009, 60, 1944-1956.
161. Mameli, G.; Poddighe, L.; Mei, A.; Uleri, E.; Sotgiu, S.; Serra, C.; Manetti, R.; Dolei, A. Expression and activation by epstein barr virus of human endogenous retroviruses-w in blood cells and astrocytes: Inference for multiple sclerosis. PloS one 2012, 7, e44991.
162. Perron, H.; Lalande, B.; Gratacap, B.; Laurent, A.; Genoulaz, O.; Geny, C.; Mallaret, M.; Schuller, E.; Stoebner, P.; Seigneurin, J.M. Isolation of retrovirus from patients with multiple sclerosis. Lancet 1991, 337, 862-863.
163. Garson, J.A.; Tuke, P.W.; Giraud, P.; Paranhos-Baccala, G.; Perron, H. Detection of virion-associated MSRV-RNA in serum of patients with multiple sclerosis. Lancet 1998, 351, 33.
164. Dolei, A.; Serra, C.; Mameli, G.; Pugliatti, M.; Sechi, G.; Cirotto, M.C.; Rosati, G.; Sotgiu, S. Multiple sclerosis-associated retrovirus (MSRV) in Sardinian MS patients. Neurology 2002, 58, 471-473.
165. Perron, H.; Jouvin-Marche, E.; Michel, M.; Ounanian-Paraz, A.; Camelo, S.; Dumon, A.; Jolivet-Reynaud, C.; Marcel, F.; Souillet, Y.; Borel, E. et al. Multiple sclerosis retrovirus particles and recombinant envelope trigger an abnormal immune response in vitro, by inducing polyclonal Vbeta16 T-lymphocyte activation. Virology 2001, 287, 321-332.
166. Serra, C.; Mameli, G.; Arru, G.; Sotgiu, S.; Rosati, G.; Dolei, A. in vitro modulation of the multiple sclerosis (MS)-associated retrovirus by cytokines: implications for MS pathogenesis. Journal of Neurovirology 2003, 9, 637-643.
167. Rolland, A.; Jouvin-Marche, E.; Saresella, M.; Ferrante, P.; Cavaretta, R.; Creange, A.; Marche, P.; Perron, H., Correlation between disease severity and in vitro cytokine production mediated by MSRV (multiple sclerosis associated retroviral element) envelope protein in patients with multiple sclerosis. Journal of Neuroimmunology 2005, 160, 195-203.
168. Saresella, M.; Rolland, A.; Marventano, I.; Cavarretta, R.; Caputo, D.; Marche, P.; Perron, H.; Clerici, M. Multiple sclerosis-associated retroviral agent (MSRV)-stimulated cytokine production in patients with relapsing-remitting multiple sclerosis. Mult. Scler. 2009, 15, 443-447.
169. Fujinami, R.S.; Oldstone, M.B.; Wroblewska, Z.; Frankel, M.E.; Koprowski, H. Molecular mimicry in virus infection: crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. Proceedings of the National Academy of Sciences of the United States of America 1983, 80, 2346-2350.
170. Wucherpfennig, K.W.; Strominger, J.L. Molecular mimicry in T-cell-mediated autoimmunity: Viral peptides activate human T-cell clones specific for myelin basic protein. Cell 1995, 80, 695-705.
171. Gross, D.M.; Forsthuber, T.; Tary-Lehmann, M.; Etling, C.; Ito, K.; Nagy, Z.A.; Field, J.A.; Steere, A.C.; Huber, B.T. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 1998, 281, 703-706.
172. Munz, C.; Lunemann, J.D.; Getts, M.T.; Miller, S.D. Antiviral immune responses: Triggers of or triggered by autoimmunity? Nature reviews. Immunology 2009, 9, 246-258.
173. James, J.A.; Harley, J.B. Linear epitope mapping of an Sm B/B' polypeptide. J. Immunol. 1992, 148, 2074-2079.
174. Sabbatini, A.; Bombardieri, S.; Migliorini, P. Autoantibodies from patients with systemic lupus erythematosus bind a shared sequence of SmD and Epstein-Barr virus-encoded nuclear antigen EBNA I. European Journal of Immunology 1993, 23, 1146-1152.
175. James, J.A.; Scofield, R.H.; Harley, J.B. Lupus humoral autoimmunity after short peptide immunization. Annals of the New York Academy of Sciences 1997, 815, 124-127.
176. Sundar, K.; Jacques, S.; Gottlieb, P.; Villars, R.; Benito, M.E.; Taylor, D.K.; Spatz, L.A. Expression of the Epstein-Barr virus nuclear antigen-1 (EBNA-1) in the mouse can elicit the production of anti-dsDNA and anti-Sm antibodies. Journal of Autoimmunity 2004, 23, 127-140.
177. McClain, M.T.; Heinlen, L.D.; Dennis, G.J.; Roebuck, J.; Harley, J.B.; James, J.A. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nature Medicine 2005, 11, 85-89.
178. Vossenaar, E.R.; Zendman, A.J.; van Venrooij, W.J.; Pruijn, G.J. PAD A growing family of citrullinating enzymes: genes, features and involvement in disease. BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology 2003, 25, 1106-1118.
179. Pratesi, F.; Tommasi, C.; Anzilotti, C.; Chimenti, D.; Migliorini, P. Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis and Rheumatism 2006, 54, 733-741.
180. Bax, M.; van Heemst, J.; Huizinga, T.W.; Toes, R.E. Genetics of rheumatoid arthritis: What have we learned? Immunogenetics 2011, 63, 459-466.
181. Roudier, J.; Petersen, J.; Rhodes, G.H.; Luka, J.; Carson, D.A. Susceptibility to rheumatoid arthritis maps to a T-cell epitope shared by the HLA-Dw4 DR beta-1 chain and the Epstein-Barr virus glycoprotein gp110. Proceedings of the National Academy of Sciences of the United States of America 1989, 86, 5104-5108.
182. La Cava, A.; Nelson, J.L.; Ollier, W.E.; MacGregor, A.; Keystone, E.C.; Thorne, J.C.; Scavulli, J.F.; Berry, C.C.; Carson, D.A.; Albani, S. Genetic bias in immune responses to a cassette shared by different microorganisms in patients with rheumatoid arthritis. The Journal of Clinical Investigation 1997, 100, 658-663.
183. Lang, H.L.; Jacobsen, H.; Ikemizu, S.; Andersson, C.; Harlos, K.; Madsen, L.; Hjorth, P.; Sondergaard, L.; Svejgaard, A.; Wucherpfennig, K.; et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nature Immunology 2002, 3, 940-943.
184. Gregersen, J.W.; Kranc, K.R.; Ke, X.; Svendsen, P.; Madsen, L.S.; Thomsen, A.R.; Cardon, L.R.; Bell, J.I.; Fugger, L. Functional epistasis on a common MHC haplotype associated with multiple sclerosis. Nature 2006, 443, 574-577.
185. Lunemann, J.D.; Jelcic, I.; Roberts, S.; Lutterotti, A.; Tackenberg, B.; Martin, R.; Munz, C. EBNA1-specific T-cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. The Journal of Experimental Medicine 2008, 205, 1763-1773.
186. van Noort, J.M.; van Sechel, A.C.; Bajramovic, J.J.; el Ouagmiri, M.; Polman, C.H.; Lassmann, H.; Ravid, R. The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature 1995, 375, 798-801.
187. van Sechel, A.C.; Bajramovic, J.J.; van Stipdonk, M.J.; Persoon-Deen, C.; Geutskens, S.B.; van Noort, J.M. EBV-induced expression and HLA-DR-restricted presentation by human B-cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis. J. Immunol. 1999, 162, 129-135.
188. van Noort, J.M.; Bajramovic, J.J.; Plomp, A.C.; van Stipdonk, M.J. Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis. Journal of Neuroimmunology 2000, 105, 46-57.
189. Ousman, S.S.; Tomooka, B.H.; van Noort, J.M.; Wawrousek, E.F.; O'Connor, K.C.; Hafler, D.A.; Sobel, R.A.; Robinson, W.H.; Steinman, L., Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature 2007, 448, 474-479.
190. Rand, K.H.; Houck, H.; Denslow, N.D.; Heilman, K.M. Molecular approach to find target(s) for oligoclonal bands in multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry 1998, 5, 48-55.
191. Wucherpfennig, K.W. Mechanisms for the induction of autoimmunity by infectious agents. The Journal of Clinical Investigation 2001, 108, 1097-1104.
192. Sospedra, M.; Martin, R. Immunology of multiple sclerosis. Annual Review of Immunology 2005, 23, 683-747.
193. Libbey, J.E.; Fujinami, R.S. Potential triggers of MS. Results and Problems in Cell Differentiation 2010, 51, 21-42.
194. Lehmann, P.V.; Forsthuber, T.; Miller, A.; Sercarz, E.E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992, 358, 155-157.
195. Miller, S.D.; Vanderlugt, C.L.; Begolka, W.S.; Pao, W.; Yauch, R.L.; Neville, K.L.; Katz-Levy, Y.; Carrizosa, A.; Kim, B.S. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nature Medicine 1997, 3, 1133-1136.
196. Odumade, O.A.; Knight, J.A.; Schmeling, D.O.; Masopust, D.; Balfour, H.H., Jr.; Hogquist, K.A. Primary Epstein-Barr virus infection does not erode preexisting CD8(+) T-cell memory in humans. The Journal of Experimental Medicine 2012, 209, 471-478.
197. Bar-Or, A.; Fawaz, L.; Fan, B.; Darlington, P.J.; Rieger, A.; Ghorayeb, C.; Calabresi, P.A.; Waubant, E.; Hauser, S.L.; Zhang, J.; et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Annals of Neurology 2010, 67, 452-461.
198. Cusick, M.F.; Libbey, J.E.; Fujinami, R.S. Molecular mimicry as a mechanism of autoimmune disease. Clinical Reviews in Allergy & Immunology 2012, 42, 102-111.
199. Ji, Q.; Perchellet, A.; Goverman, J.M. Viral infection triggers central nervous system autoimmunity via activation of CD8+ T-cells expressing dual TCRs. Nature Immunology 2010, 11, 628-634.
200. Bernasconi, N.L.; Traggiai, E.; Lanzavecchia, A. Maintenance of serological memory by polyclonal activation of human memory B-cells. Science 2002, 298, 2199-2202.
201. Desai-Mehta, A.; Lu, L.; Ramsey-Goldman, R.; Datta, S.K. Hyperexpression of CD40 ligand by B and T-cells in human lupus and its role in pathogenic autoantibody production. The Journal of Clinical Investigation 1996, 97, 2063-2073.
202. Huang, W.X.; Huang, P.; Hillert, J. Systemic upregulation of CD40 and CD40 ligand mRNA expression in multiple sclerosis. Mult. Scler. 2000, 6, 61-65.
203. Sofo, V.; Salmeri, F.M.; Di Bella, P.; Sessa, E.; D'Aleo, G.; Trimarchi, G.; Bramanti, P. Short communication: Impairment of membrane markers on peripheral blood mononuclear cells and imbalance of cytokine secretion in the pathogenesis of multiple sclerosis active phases. Journal of Interferon & Cytokine Research: The Official Journal of the International Society for Interferon and Cytokine Research 2005, 25, 661-665.
204. Komatsuda, A.; Wakui, H.; Iwamoto, K.; Ozawa, M.; Togashi, M.; Masai, R.; Maki, N.; Hatakeyama, T.; Sawada, K. Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clinical and Experimental Immunology 2008, 152, 482-487.
205. Alaaeddine, N.; Hassan, G.S.; Yacoub, D.; Mourad, W. CD154: An immunoinflammatory mediator in systemic lupus erythematosus and rheumatoid arthritis. Clinical & Developmental Immunology 2012, doi: 10.1155/2012/490148.
206. Chamberlain, N.D.; Kim, S.J.; Vila, O.M.; Volin, M.V.; Volkov, S.; Pope, R.M.; Arami, S.; Mandelin, A.M., 2nd; Shahrara, S. Ligation of TLR7 by rheumatoid arthritis synovial fluid single strand RNA induces transcription of TNFalpha in monocytes. Annals of the Rheumatic Diseases 2012, doi: 10.1136/annrheumdis-2011-201203.
207. Vandvik, B.; Norrby, E. Oligoclonal IgG antibody response in the central nervous system to different measles virus antigens in subacute sclerosing panencephalitis. Proceedings of the National Academy of Sciences of the United States of America 1973, 70, 1060-1063.
208. Vartdal, F.; Vandvik, B.; Michaelsen, T.E.; Loe, K.; Norrby, E. Neurosyphilis: Intrathecal synthesis of oligoclonal antibodies to Treponema pallidum. Annals of Neurology 1982, 11, 35-40.
209. Vartdal, F.; Vandvik, B.; Norrby, E. Viral and bacterial antibody responses in multiple sclerosis. Annals of Neurology 1980, 8, 248-255.
210. Vartdal, F.; Vandvik, B. Multiple sclerosis. Electrofocused "bands" of oligoclonal CSF IgG do not carry antibody activity against measles, varicella-zoster or rotaviruses. Journal of the Neurological Sciences 1982, 54, 99-107.
211. Owens, G.P.; Ritchie, A.M.; Gilden, D.H.; Burgoon, M.P.; Becker, D.; Bennett, J.L. Measles virus-specific plasma cells are prominent in subacute sclerosing panencephalitis CSF. Neurology 2007, 68, 1815-1819.
212. Ahlgren, C.; Oden, A.; Bergstrom, T.; Lycke, J. Serum and CSF measles antibody levels increase over time in patients with multiple sclerosis or clinically isolated syndrome. Journal of Neuroimmunology 2012, 247, 70-74.
213. Sundstrom, P.; Juto, P.; Wadell, G.; Hallmans, G.; Svenningsson, A.; Nystrom, L.; Dillner, J.; Forsgren, L. An altered immune response to Epstein-Barr virus in multiple sclerosis: A prospective study. Neurology 2004, 62, 2277-2282.
214. Sellner, J.; Cepok, S.; Kalluri, S.R.; Nestler, A.; Kleiter, I.; Kumpfel, T.; Linker, R.; Melms, A.; Menge, T.; Tumani, H.; et al. Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes viruses. Neurochemistry International 2010, 57, 662-667.
215. Hogan, L.H.; Co, D.O.; Karman, J.; Heninger, E.; Suresh, M.; Sandor, M. Virally activated CD8 T-cells home to Mycobacterium bovis BCG-induced granulomas but enhance antimycobacterial protection only in immunodeficient mice. Infection and Immunity 2007, 75, 1154-1166.
216. Vossenkamper, A.; Lutalo, P.M.; Spencer, J. Translational Mini-Review Series on B-cell subsets in disease. Transitional B-cells in systemic lupus erythematosus and Sjogren's syndrome: Clinical implications and effects of B-cell-targeted therapies. Clinical and Experimental Immunology 2012, 167, 7-14.
217. Marston, B.; Palanichamy, A.; Anolik, J.H. B-cells in the pathogenesis and treatment of rheumatoid arthritis. Current Opinion in Rheumatology 2010, 22, 307-315.
218. Meier, U.C.; Giovannoni, G.; Tzartos, J.S.; Khan, G. Translational Mini-Review Series on B-cell subsets in disease. B-cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein-Barr virus entry to the central nervous system? Clinical and Experimental Immunology 2012, 167, 1-6.
219. Babcock, G.J.; Decker, L.L.; Volk, M.; Thorley-Lawson, D.A. EBV persistence in memory B-cells in vivo. Immunity 1998, 9, 395-404.
220. Yajima, M.; Imadome, K.; Nakagawa, A.; Watanabe, S.; Terashima, K.; Nakamura, H.; Ito, M.; Shimizu, N.; Honda, M.; Yamamoto, N.; et al. A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. The Journal of Infectious Diseases 2008, 198, 673-682.
221. Ma, S.D.; Hegde, S.; Young, K.H.; Sullivan, R.; Rajesh, D.; Zhou, Y.; Jankowska-Gan, E.; Burlingham, W.J.; Sun, X.; Gulley, M.L.; et al. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. Journal of Virology 2011, 85, 165-177.
222. Kuwana, Y.; Takei, M.; Yajima, M.; Imadome, K.; Inomata, H.; Shiozaki, M.; Ikumi, N.; Nozaki, T.; Shiraiwa, H.; Kitamura, N.; et al. Epstein-Barr virus induces erosive arthritis in humanized mice. PloS one 2011, 6, e26630.
223. Greenblatt, M.B.; Vbranac, V.; Tivey, T.; Tsang, K.; Tager, A.M.; Aliprantis, A.O. Graft versus host disease in the bone marrow, liver and thymus humanized mouse model. PloS one 2012, 7, e44664.
224. Cohen, J.I.; Fauci, A.S.; Varmus, H.; Nabel, G.J. Epstein-Barr virus: an important vaccine target for cancer prevention. Science Translational Medicine 2011, 3, 107fs7.
225. Sokal, E.M.; Hoppenbrouwers, K.; Vandermeulen, C.; Moutschen, M.; Leonard, P.; Moreels, A.; Haumont, M.; Bollen, A.; Smets, F.; Denis, M. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. The Journal of Infectious Diseases 2007, 196, 1749-1753.